[1] Kuvin JT, Kimmelstiel CD. Infection causes of atherosclerosis. Am Heart J. 1999;(137):216-226.
[2] Hatanaka K, Li XA, Masuda K, et al. Immunohistochemical localization of C-reactive protein binding sites in human aortic lesions by a modified streptavid in-biotin-staining method. Pathol Int. 1995(3):635-641.
[3] Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocates with the teruninal complement complex in the intima of early atherosclerotic lesions of human coronaryarteries. Arterioscler Thromb Vasc Biol. 1998(6):1386-1392.
[4] 邓新桃,何情,赵建祥,等.冠状动脉病变严重程度、冠心病介人治疗对QT离散度的影响[J].实用临床医药杂志,2007,(1):95-96.
[5] 张文利,黄定.PCI后冠状动脉再狭窄机制及防治研究进展[J].中国循证心血管医学杂志,2011,3(2):125-128.
[6] Komowski R, Hong MK, Tio FO, et al. In-stent retenosis: contribution of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1): 224-230.
[7] 徐伟斌,俞璐,罗敏.内脏素-又一新的脂肪因子[J].中国糖尿病杂志,2006,14:153-154.
[8] Fukuhara A, Matsuda M, Nishizawa M, et al. Vacating: a protein secreted by visceral fat thatmimics the effects of insulin. Science. 2005;307(5708):426-430.
[9] Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2):1431-1437.
[10] Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation. 2007; 115(8):972-980.
[11] Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflamma- tory and immunomodulating properties. J Immunol. 2007;178(3):1748-1758.
[12] 李虎,秦涛,贾国良,等.直接支架植入术对冠脉循环白细胞及血小板功能的影响[J].中国现代医学杂志, 2007,15(13): 1989-1991.
[13] 李璇,马根山,陈忠,等.川芎嗪洗脱支架对猪冠状动脉平滑肌细胞增殖和凋亡的影响[J].现代医学, 2008,36(4):236-239.
[14] 贡军丽,王瑛,杨德琼,等.冠状动脉介入治疗后相关细胞因子含量的变化及其意义[J].心血管康复医学杂志, 2008,17(5):428-430.
[15] 卢长青,邱春光,宋文翔,等. 冠脉内置入药物涂层支架与金属裸支架对血浆C反应蛋白水平影响的对比观察[J].河南医学研究, 2007,16(4):311-313.
[16] Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest. 2008;38(1):71-72.
[17] Iwen KA, Senyaman O, Schwartz A, et al. Melanocortin crosstalk with adipose functions: ACTH directly induces insulin resistance, promotes a pro-inflammatory adipokine profile and stimulates UCP-1 in adipocytes. J Endocrinol. 2008;196(3):465-472.
[18] Adya R, Tan BK, Puan A, et al. Visfatin induces human endothelial VEGF and MMP-2 /9 production via MAPK and P13K/Akt signaling pathways:novel insights into visfatin induced angiogenesis. Cardiovase Res. 2008;78(2): 356-365.
[19] Hatanaka K, L iX A, M asudaK, et al. Immunohistochemical localization of C-reactive protein binding sites in humanaortic lesionsbya modified streptavid in-biotin-staining method. Pathol Int. 1995;45:635-641.
[20] Zwaka TP, Hombach V, Torzewski J. C-reactive protein mediated low density lipoprotein uptake bymacrophages implications for atherosclerosis. Circulation. 2001;103(9): 1194-1197.
[21] Tataru MC, Heinrich J, Junker R, et al. C-reactive protein and the sever ity of atherosc leros is in m yocard ial in farction patients with stable angina pectoris. Eur Heart J. 2000;21(12): 1000-1008.
[22] 张慧平,孙福成,季福绥,等.C-反应蛋白与冠心病关系的研究[J].心血管康复医学杂志,2007,16:223-225.
[23] 王文清,宁波,王新宴,等.C-反应蛋白与冠心病病变程度的相关性[J].心脏杂志,2006,(3):323-325.
[24] Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteinase 2 and 9 are elevated in patients with acute coronary syndrome. J Am Coll Cardiol. 1998;32(2): 368-372.
[25] Huang T, Cheng J, Zheng YF. In vitro degradation and biocompatibility of Fe-Pd and Fe-Pt composites fabricated by spark plasma sintering. Mater Sci Eng C Mater Biol Appl. 2014;35:43-53.
[26] Li L, Mirhosseini N, Michael A, et al. Enhancement of endothelialisation of coronary stents by laser surface engineering. Lasers Surg Med. 2013;45(9):608-616.
[27] Martin D, Boyle F. Finite element analysis of balloon-expandable coronary stent deployment: influence of angioplasty balloon configuration. Int J Numer Method Biomed Eng. 2013;29(11):1161-1175.
[28] Boyle CJ, Lennon AB, Prendergast PJ. Application of a mechanobiological simulation technique to stents used clinically. J Biomech. 2013;46(5):918-924.
[29] Walker AM, Johnston CR, Rival DE. The quantification of hemodynamic parameters downstream of a Gianturco Zenith stent wire using newtonian and non-newtonian analog fluids in a pulsatile flow environment. J Biomech Eng. 2012; 134(11): 111001.
[30] Tambaca J, Canic S, Kosor M, et al. Mechanical behavior of fully expanded commercially available endovascular coronary stents. Tex Heart Inst J. 2011;38(5):491-501.
[31] Crowder SW, Gupta MK, Hofmeister LH, et al. Modular polymer design to regulate phenotype and oxidative response of human coronary artery cells for potential stent coating applications. Acta Biomater. 2012;8(2):559-569.
[32] Gastaldi D, Sassi V, Petrini L, et al. Continuum damage model for bioresorbable magnesium alloy devices - application to coronary stents. J Mech Behav Biomed Mater. 2011;4(3): 352-365.
[33] Boyle CJ, Lennon AB, Early M, et al. Computational simulation methodologies for mechanobiological modelling: a cell-centred approach to neointima development in stents. Philos Trans A Math Phys Eng Sci. 2010;368(1921):2919-2935.
[34] Karagkiozaki VC, Logothetidis SD, Kassavetis SN, et al. Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int J Nanomedicine. 2010;5:239-248. |